Impact of palifermin on intestinal mucositis of HSCT recipients after BEAM.
The matched-control study failed to show a clinical relevant impact of palifermin on intestinal mucositis, although there was a reduced inflammatory response and less febrile neutropenia among patients who had no bacteraemia.